Therapeutic drug monitoring of teicoplanin using an LC–MS/MS method: Analysis of 421 measurements in a naturalistic clinical setting

Publication date: 15 April 2019Source: Journal of Pharmaceutical and Biomedical Analysis, Volume 167Author(s): Jaewan Jung, Kyunghoon Lee, Jongwon Oh, Rihwa Choi, Hye In Woo, Hyung-Doo Park, Cheol-In Kang, Yae-Jean Kim, Soo-Youn LeeAbstractTeicoplanin is a glycopeptide antibiotic used for treatment of severe Gram-positive bacterial infection. The aim of this study was to develop and validate a liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for therapeutic drug monitoring (TDM) of teicoplanin and to review our clinical experience.We established an LC–MS/MS method to analyze serum concentration of teicoplanin using simple protein precipitation with a 5 min run time for each sample. The linearity, lower limit of quantitation, detection accuracy, precision, carryover, matrix effect, and extraction recovery were evaluated. From September 2014 to June 2017, a total of 421 serum teicoplanin concentrations was measured in 223 patients. We collected demographic and clinical data, medication history, and laboratory findings through retrospective review of medical records.The LC–MS/MS method was linear for serum teicoplanin concentrations in the range of 12.0–89.0 μg/mL. The intra- and inter-assay precisions were below CV 7.5%. The accuracy was less than ±10% bias. The lower limit of quantification was 0.2 μg/mL. The extraction recovery ranged from 88.8% to 96.6%. Of 421 measurements, 87 (20.7%) were subtherapeutic (< 10 μg/mL), and four (0.9%) ...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research